CANF Can-Fite BioPharma Ltd. Stock Quote

CANF [AMEX]

Index	-	P/E	-	EPS (ttm)	-1.47	Insider Own	1.19%	Shs Outstand	15.41M	Perf Week	1.06%
Market Cap	29.29M	Forward P/E	-	EPS next Y	-0.68	Insider Trans	0.00%	Shs Float	14.76M	Perf Month	0.00%
Income	-	PEG	-	EPS next Q	-0.26	Inst Own	6.52%	Short Float	1.73%	Perf Quarter	-11.83%
Sales	0.81M	P/S	36.38	EPS this Y	62.70%	Inst Trans	-	Short Ratio	0.54	Perf Half Y	-8.65%
Book/sh	0.63	P/B	3.02	EPS next Y	44.70%	ROA	-	Target Price	-	Perf Year	-30.91%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	1.08 - 2.95	Perf YTD	6.74%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-35.59%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	75.93%	ATR	0.10
Employees	8	Current Ratio	-	Sales Q/Q	-81.70%	Oper. Margin	-	RSI (14)	55.01	Volatility	5.13% 4.30%
Optionable	No	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.86	Prev Close	1.89
Shortable	Yes	LT Debt/Eq	-	Earnings	Nov 30 BMO	Payout	-	Avg Volume	469.66K	Price	1.90
Recom	2.00	SMA20	2.48%	SMA50	2.82%	SMA200	-0.83%	Volume	403,615	Change	0.53%

Aug-11-17

Initiated

Maxim Group

Buy

Oct-19-16

Resumed

ROTH Capital

Buy

Aug-29-16

Resumed

Rodman & Renshaw

Buy

Nov-30-15

Reiterated

H.C. Wainwright

Buy

$4 → $6

Mar-31-15

Reiterated

H.C. Wainwright

Buy

$7 → $3

Mar-30-15

Downgrade

ROTH Capital

Buy → Neutral

$20 → $2.40

Dec-29-14

Reiterated

ROTH Capital

Buy

$28 → $20

Nov-18-14

Initiated

H.C. Wainwright

Buy

Jan-08-21 07:00AM	Can-Fite Announces Publication of Namodenoson Liver Cancer Study in Peer Reviewed JournalCancers Business Wire
Jan-04-21 07:00AM	Can-Fite to Present at Biotech Showcase Digital 2021 Newsfile
Dec-22-20 06:00AM	CANF: Multiple Shots on Goal Make Can-Fite an Intriguing Opportunity Zacks Small Cap Research
Dec-15-20 07:00AM	Can-Fite Receives Israel Ministry of Health Approval to Conduct Research with Cannabinoids in Cancer, Inflammation and Obesity at the Company Discovery Labs Business Wire
Dec-14-20 07:00AM	Can-Fite Reports on Progress With Its Namodenoson NASH Program Business Wire
Dec-03-20 07:00AM	Can-Fite to Present at Benzinga Global Small Cap Conference on December 8, 2020 Business Wire
Nov-30-20 07:00AM	Can-Fite Reports Third Quarter 2020 Financial Results & Provides Clinical Update Business Wire
Nov-24-20 07:00AM	Can-Fites Namodenoson Abstract Selected as Best of The Liver Meeting in the NASH Category of the American Association of Liver Diseases (AASLD) Business Wire
Nov-23-20 07:00AM	Can-Fite to Conduct Investor Call to Review Q3 Results and Provide Business Update on Monday, November 30, 2020 at 9:15 a.m. ET Business Wire
Nov-16-20 07:00AM	Can-Fite Presented NASH Phase II Namodenoson Data at a Late Breaking Session of the American Association for the Study of Liver Diseases (AASLD) Conference Business Wire
Nov-09-20 07:00AM	Can-Fite to Present its NASH Program in Fireside Chat at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020 Business Wire +6.82%
Oct-15-20 08:03AM	The Daily Biotech Pulse: Vertex Pulls Plug On Protein Deficiency Drug, FDA Nod For Regeneron's Ebola Treatment, Can Fite Issues Psoriasis Readout Benzinga +5.64%
Oct-13-20 07:00AM	Can-Fite to Host Conference Call to Update Shareholders on Positive Interim Results of its Phase III Psoriasis Study on October 15, 2020 Business Wire
Oct-06-20 07:30AM	Can-Fite Announces Positive Phase III Psoriasis Interim Data Analysis Business Wire +5.14%
Sep-30-20 07:00AM	Can-Fite Selected to Deliver Late-Breaking Oral Presentation on Namodenosons Treatment of NASH at American Association for the Study of Liver Diseases Conference Business Wire
Sep-22-20 07:00AM	Can-Fite to Participate in Two BioPharma Partnering Conferences Business Wire
Sep-08-20 07:00AM	Can-Fite to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 Business Wire +5.59%
Aug-31-20 05:00PM	LD Micro 360 Companies Set to Present this Week ACCESSWIRE
07:00AM	FDA Clears Can-Fite to Commence Phase II COVID-19 Study Business Wire
Aug-27-20 07:00AM	Can-Fite Reports Second Quarter 2020 Financial Results & Provides Clinical Update Business Wire
Aug-26-20 07:00AM	Can-Fite to Present at The LD Micro 500 Virtual Conference on September 1, 2020 ACCESSWIRE
Aug-25-20 08:09AM	Can-Fite Receives Notification of Patent Grant from European Patent Office for Namodenoson in the Treatment of NASH Business Wire
Aug-20-20 07:00AM	Can-Fite to Conduct Investor Call to Review Q2 Results and Provide Business Update on Thursday, August 27, 2020 at 4:15 p.m. ET Business Wire -9.34%
Aug-05-20 09:00AM	LD Micro - Announces Preliminary List of Presenters for the LD-500 ACCESSWIRE -9.24%
Jul-27-20 07:00AM	Can-Fite Submits Investigational New Drug Application to U.S. FDA for COVID-19 Phase II Study Business Wire
Jul-20-20 07:00AM	Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds Business Wire
Jul-15-20 07:00AM	Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance, Plans to File IND Shortly Business Wire +10.87%
Jul-06-20 08:00AM	Can-Fite Announces $3.4 Million Registered Direct Offering Business Wire -12.50%
Jun-30-20 07:00AM	Can-Fite Announces Final Data Analysis from Phase II NASH Study: Highly Significant and Sustained Reduction in Liver Fat Volume Throughout Study Period Business Wire -9.59%
Jun-10-20 08:00AM	Can-Fite Announces $8.0 Million Registered Direct Offering Business Wire -19.47%
Jun-09-20 07:00AM	Following Pre-IND Guidance from FDA Can-Fite to Advance Piclidenoson into Phase II COVID-19 Trial in the U.S. Business Wire +10.24%
Jun-08-20 07:25AM	Can-Fite Participating in BIO Digital International Convention and One-on-One Partnering Meetings on June 8-12, 2020 Business Wire +6.77%
Jun-04-20 07:14AM	Can-Fite Concludes Successful Meeting with European Medicines Agency (EMA) Regarding Phase III Trial and Registration Plan for Namodenoson in the Treatment of Liver Cancer Business Wire
Jun-03-20 07:00AM	Can-Fite BioPharma to Hold Investor Webinar and Q&A Session with CEO on June 4th Business Wire
Jun-01-20 07:00AM	Can-Fite Reports First Quarter 2020 Financial Results & Provides Clinical Update Business Wire
06:30AM	Can-Fite BioPharma Ltd. to Host Earnings Call ACCESSWIRE
May-28-20 07:00AM	Can-Fite to Host First Quarter 2020 Financial Results & Clinical Update Conference Call on June 1, 2020 Business Wire
May-21-20 07:00AM	Can-Fite Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent and Trademark Office Business Wire +9.05%
May-18-20 07:00AM	Can-Fite Reports Additional Findings from Successful Phase II NASH Study: 25 mg Dose of Namodenoson Significantly Reduced Liver Fat and Fibrosis Business Wire +8.70%
May-15-20 07:00AM	Can-Fite Announces Pre-IND Submission to U.S. FDA for Piclidenoson in the Treatment of COVID-19 Infected Patients with Moderate-to-Severe Symptoms Business Wire
Apr-28-20 11:04AM	Top Ranked Momentum Stocks to Buy for April 28th Zacks
Apr-27-20 09:48AM	Top Ranked Momentum Stocks to Buy for April 27th Zacks
Apr-14-20 07:00AM	Can Fite to Conduct Investor Call to Review Positive Phase II NASH Data on Thursday, April 16, 2020 at 4:05 p.m. ET Business Wire -7.14%
Apr-13-20 09:54AM	Biocept To Begin COVID-19 Testing; BioCryst, Athersys, Can-Fite To Research Potential Treatments In Clinics Benzinga +35.17%
06:30AM	Can Fite Received Approval for COVID-19 Clinical Trial in Israel, Patient Enrollment and Dosing to Commence Immediately Business Wire
Apr-07-20 09:00AM	Can-Fite Reports Positive Top Line Results from its Phase II NASH Study with Namodenoson Business Wire
Mar-30-20 07:00AM	Can-Fite Implements Interim Analysis for its Phase III Psoriasis Trial with Data Expected Q4 2020 Business Wire
Mar-27-20 07:00AM	Can-Fite Reports 2019 Financial Results & Provides Clinical Development Update Business Wire
Mar-23-20 07:45AM	Can-Fite: Piclidenoson is Submitted for Compassionate Use Treatment for Coronavirus Patients in Israel Business Wire
Mar-18-20 07:00AM	Can-Fite to Participate in Digital Bio-Europe Spring Partnering Conference; Looks to Partner on Co-Development of Piclidenoson for Coronavirus Treatment Business Wire
Mar-16-20 07:00AM	Can-Fite: Progress in Compassionate Use Program Treating Advanced Liver Cancer Patients with Namodenoson Business Wire
Mar-13-20 10:53AM	The Latest Coronavirus Developments From Biotechs: La Jolla Provides Giapreza In Italy, Enanta Researches Antivirals Benzinga +9.02%
08:13AM	Benzinga Pro's Top 5 Stocks To Watch For Fri., Mar. 13, 2020: GLD, OPK, IBIO, CPB, CANF Benzinga
07:54AM	Can-Fite Surges on Study Hopes for Arthritis Drug in Coronavirus Treatment TheStreet.com
07:00AM	Can-Fite to Explore the anti-Coronavirus Effects of Piclidenoson in Collaboration with Lewis Katz School of Medicine at Temple University Business Wire
Mar-11-20 11:06AM	Biotech Stock Roundup: NVAX, CANF Up on Coronavirus Treatment Updates & More Zacks +14.29%
07:30AM	Can-Fite: New Pre-clinical Studies Demonstrate Inhibition of Fat Cell Expansion by Cannabis Derived CBD Business Wire
Mar-06-20 10:45AM	Can-Fite (CANF) to Explore RA Drug for Coronavirus Treatment Zacks -15.66%
Mar-05-20 08:05AM	The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19 Benzinga +26.92%
07:00AM	Can-Fite Updates on Clinical Milestone for its Phase III Rheumatoid Arthritis Study with Piclidenoson; Drugs Combating Rheumatoid Arthritis are Currently Introduced for the Treatment of the Coronavirus Business Wire
Mar-03-20 07:00AM	Can-Fite is Filing Drug Safety Update Report Showing Positive Safety Results from Phase II and Phase III Studies of Namodenoson and Piclidenoson Business Wire +12.60%
Feb-27-20 06:00AM	Pre-clinical Studies Demonstrate CBDs Robust Anti-Cancer Effect Against Liver Cancer; Can-Fite and Univo Pharmaceuticals Expand Collaboration Agreement Business Wire
Feb-24-20 07:00AM	Can Fite Files Patent for Namodenoson to Overcome Drug Resistance to Checkpoint Inhibitors for Oncology Indications Business Wire
Feb-18-20 07:10AM	Can-Fite Granted Patent Allowance for its NASH Drug Namodenoson in South Korea; Results of its NASH Phase II Study are Expected this Quarter Business Wire +5.42%
Feb-13-20 07:00AM	Can-Fite Submits Liver Cancer Phase III Protocol and Registration Plan to EMA for Namodenoson Business Wire +7.96%
Feb-10-20 02:48PM	Can-Fite BioPharma Announces Pricing of $5 Million Public Offering GlobeNewswire -43.13%
Feb-03-20 07:30AM	Can-Fite Completes 50% Patient Enrollment in Phase III Rheumatoid Arthritis Study & Implements Interim Analysis Business Wire
Jan-16-20 07:00AM	Can-Fite and Univo Pharmaceuticals Collaboration Result in Discovery and Applied Patent for Cannabinoid Formulations with Broad Therapeutic Effects Business Wire
Jan-09-20 09:10AM	Can-Fite Announces Exercise of Warrants for Cash Proceeds of $2.4 Million Business Wire -19.65%
Jan-07-20 08:20AM	Data from the Phase II Liver Cancer Study with Namodenoson will be presented at the ISCORT Conference by Dr. Stemmer Business Wire
Jan-06-20 10:06AM	Company News For Jan 6, 2020 Zacks
07:00AM	Can-Fite CEO Issues Letter to Shareholders Business Wire
Jan-03-20 07:00AM	New Data From Hadassah Medical Center Lab Show Can-Fites Namodenoson Induces Weight Loss Business Wire +12.82%
Dec-30-19 09:17AM	CEO Of Univo Pharmaceuticals Appointed Board Member At Can-Fite Benzinga -8.99%
Dec-27-19 10:02AM	Company News For Dec 27, 2019 Zacks -11.31%
Dec-26-19 07:00AM	Golan Bitton Univo Pharmaceutical CEO Elected to the Can-Fite Board: A Strategic Partnership with Univo to Develop Cannabinoid-Based Products is Ongoing Business Wire +30.54%
Dec-09-19 08:15AM	Can-Fite Completes 50% Patient Enrollment in its Phase III Psoriasis Trial Business Wire
Dec-05-19 07:00AM	Can-Fite to Attend BioFIT 2019 Conference in Europe with Focus on Partnering Meetings for Namodenoson in NASH Business Wire -12.05%
Nov-29-19 08:20AM	Benzinga Pro's Top 3 Stocks To Watch For Fri., Nov. 29, 2019: CANF, PCG, BBY Benzinga +37.74%
07:00AM	Can-Fite Reports Third Quarter 2019 Financial Results & Provides Clinical Update Business Wire
Nov-21-19 07:00AM	Can-Fite BioPharma to Hold Investor Webinar and Q&A Session with CEO on November 25, 2019 Business Wire
Nov-19-19 07:00AM	Can-Fite Granted Patents for its Sexual Dysfunction Drug Business Wire
Nov-11-19 09:51AM	Can-Fite Obtains Patent For Treatment Of Osteoarthritis In Mammals Benzinga
07:00AM	Can-Fite Granted U.S. Patent for Piclidenoson in the Treatment of Osteoarthritis, Positioning this Indication for Animal Health Market Business Wire
Nov-04-19 07:00AM	Can-Fite Initiates Compassionate Use Program for Namodenoson in the Treatment of Liver Cancer, Enrolls and Treats Patients Business Wire
Oct-31-19 07:00AM	U.S. FDA Agreed with Can-Fites Proposed Pivotal Phase III Trial Design to Support a New Drug Application Submission and Approval of Namodenoson in the Treatment of Liver Cancer Business Wire +12.04%
Oct-17-19 08:00AM	Can-Fite and Gebro Pharma holding European Conference on Development & Commercialization of Phase III Drug Candidate Piclidenoson in the Treatment of Rheumatoid Arthritis Business Wire +7.76%
Oct-16-19 07:00AM	Can-Fite BioPharma Interview to Air on Bloomberg International on the RedChip Money Report Business Wire +7.07%
Oct-15-19 06:30AM	Can-Fite Completes Patient Enrollment in Phase II NASH Study of Namodenoson Business Wire
Oct-10-19 07:00AM	Can Fite Announces Publication of Namodenoson NASH Mechanism of Action in International Journal of Molecular Medicine Business Wire
Sep-23-19 07:00AM	Can-Fite Presents New Data on the Treatment of Advanced Liver Cancer with Namodenoson at the ILCA Conference Business Wire +5.13%
Sep-11-19 01:16PM	A Look At Benzinga Pro's Most-Searched Tickers For September 11, 2019 Benzinga -11.01%
Sep-10-19 08:10AM	Can-Fite's stock soars on heavy volume after collaboration deal with cannabis company Univo MarketWatch +23.19%
06:03AM	Can-Fite Enters into Strategic Agreement with Univo Pharmaceuticals to Develop Cannabinoid-Based Pharmaceuticals and Assays Business Wire
05:38AM	Can-Fite Shares Surge on Univo Accord to Develop Cannabis-Based Therapeutics TheStreet.com
Aug-29-19 07:00AM	Can-Fite Reports Second Quarter 2019 Financial Results & Provides Clinical Update Business Wire -6.75%
Aug-06-19 07:00AM	Can-Fite to Treat Advanced Liver Cancer Patients with Namodenoson Under Compassionate Use Setting in Israel Business Wire
Aug-01-19 09:38AM	Can-Fite BioPharma Reports $4M Deal With Kyongbo Pharm Benzinga -7.99%
Jul-10-19 09:56AM	Can-Fite BioPharma Appeals Lawsuit Against Venture Capital Firm Benzinga +7.22%
Jun-20-19 09:00AM	All You Need to Know About Can-Fite (CANF) Rating Upgrade to Strong Buy Zacks

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience